Name | Value |
---|---|
Revenues | 0.0K |
Cost of Revenue | 6.3K |
Gross Profit | -6.3K |
Operating Expense | 2,777.9K |
Operating I/L | -2,777.9K |
Other Income/Expense | 149.5K |
Interest Income | 0.0K |
Pretax | -2,628.4K |
Income Tax Expense | -92.6K |
Net Income/Loss | -2,628.4K |
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in immune system therapeutics and diagnostics. The company's product pipeline includes REVTx-99b, a Phase Ib clinical trial candidate for chronic nasal congestion and allergic rhinitis; REVTx-200, a nonclinical stage intranasal therapy; REVTx-300, a potential therapy for chronic organ diseases; and REVDx-501, a rapid test kit for respiratory viral infections. These products are designed to address unmet medical needs and have the potential to generate revenue through commercialization and sales.